Literature DB >> 22300873

Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations.

Julie S Snowden1, Sara Rollinson, Jennifer C Thompson, Jennifer M Harris, Cheryl L Stopford, Anna M T Richardson, Matthew Jones, Alex Gerhard, Yvonne S Davidson, Andrew Robinson, Linda Gibbons, Quan Hu, Daniel DuPlessis, David Neary, David M A Mann, Stuart M Pickering-Brown.   

Abstract

The identification of a hexanucleotide repeat expansion in the C9ORF72 gene as the cause of chromosome 9-linked frontotemporal dementia and motor neuron disease offers the opportunity for greater understanding of the relationship between these disorders and other clinical forms of frontotemporal lobar degeneration. In this study, we screened a cohort of 398 patients with frontotemporal dementia, progressive non-fluent aphasia, semantic dementia or mixture of these syndromes for mutations in the C9ORF72 gene. Motor neuron disease was present in 55 patients (14%). We identified 32 patients with C9ORF72 mutations, representing 8% of the cohort. The patients' clinical phenotype at presentation varied: nine patients had frontotemporal dementia with motor neuron disease, 19 had frontotemporal dementia alone, one had mixed semantic dementia with frontal features and three had progressive non-fluent aphasia. There was, as expected, a significant association between C9ORF72 mutations and presence of motor neuron disease. Nevertheless, 46 patients, including 22 familial, had motor neuron disease but no mutation in C9ORF72. Thirty-eight per cent of the patients with C9ORF72 mutations presented with psychosis, with a further 28% exhibiting paranoid, deluded or irrational thinking, whereas <4% of non-mutation bearers presented similarly. The presence of psychosis dramatically increased the odds that patients carried the mutation. Mutation bearers showed a low incidence of motor stereotypies, and relatively high incidence of complex repetitive behaviours, largely linked to patients' delusions. They also showed a lower incidence of acquired sweet food preference than patients without C9ORF72 mutations. Post-mortem pathology in five patients revealed transactive response DNA-binding protein 43 pathology, type A in one patient and type B in three. However, one patient had corticobasal degeneration pathology. The findings indicate that C9ORF72 mutations cause some but not all cases of frontotemporal dementia with motor neuron disease. Other mutations remain to be discovered. C9ORF72 mutations are associated with variable clinical presentations and pathology. Nevertheless, the findings highlight a powerful association between C9ORF72 mutations and psychosis and suggest that the behavioural characteristics of patients with C9ORF72 mutations are qualitatively distinct. Mutations in the C9ORF72 gene may be a major cause not only of frontotemporal dementia with motor neuron disease but also of late onset psychosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22300873      PMCID: PMC3286329          DOI: 10.1093/brain/awr355

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  68 in total

1.  Tau is a candidate gene for chromosome 17 frontotemporal dementia.

Authors:  P Poorkaj; T D Bird; E Wijsman; E Nemens; R M Garruto; L Anderson; A Andreadis; W C Wiederholt; M Raskind; G D Schellenberg
Journal:  Ann Neurol       Date:  1998-06       Impact factor: 10.422

2.  The overlap of amyotrophic lateral sclerosis and frontotemporal dementia.

Authors:  Catherine Lomen-Hoerth; Thomas Anderson; Bruce Miller
Journal:  Neurology       Date:  2002-10-08       Impact factor: 9.910

3.  FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration.

Authors:  Hazel Urwin; Keith A Josephs; Jonathan D Rohrer; Ian R Mackenzie; Manuela Neumann; Astrid Authier; Harro Seelaar; John C Van Swieten; Jeremy M Brown; Peter Johannsen; Jorgen E Nielsen; Ida E Holm; Dennis W Dickson; Rosa Rademakers; Neill R Graff-Radford; Joseph E Parisi; Ronald C Petersen; Kimmo J Hatanpaa; Charles L White; Myron F Weiner; Felix Geser; Vivianna M Van Deerlin; John Q Trojanowski; Bruce L Miller; William W Seeley; Julie van der Zee; Samir Kumar-Singh; Sebastiaan Engelborghs; Peter P De Deyn; Christine Van Broeckhoven; Eileen H Bigio; Han-Xiang Deng; Glenda M Halliday; Jillian J Kril; David G Munoz; David M Mann; Stuart M Pickering-Brown; Valerie Doodeman; Gary Adamson; Shabnam Ghazi-Noori; Elizabeth M C Fisher; Janice L Holton; Tamas Revesz; Martin N Rossor; John Collinge; Simon Mead; Adrian M Isaacs
Journal:  Acta Neuropathol       Date:  2010-05-20       Impact factor: 17.088

4.  Rapidly progressive aphasic dementia with motor neuron disease: a distinctive clinical entity.

Authors:  Marco Catani; Massimo Piccirilli; Maria Concetta Geloso; Antonio Cherubini; Giancarlo Finali; Gianpiero Pelliccioli; Umberto Senin; Patrizia Mecocci
Journal:  Dement Geriatr Cogn Disord       Date:  2003-10-13       Impact factor: 2.959

Review 5.  Frontotemporal lobar degeneration: clinical and pathological relationships.

Authors:  Julie Snowden; David Neary; David Mann
Journal:  Acta Neuropathol       Date:  2007-06-14       Impact factor: 17.088

6.  Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions visualized with ubiquitin-binding protein p62 immunohistochemistry.

Authors:  Maria Pikkarainen; Päivi Hartikainen; Irina Alafuzoff
Journal:  J Neuropathol Exp Neurol       Date:  2008-04       Impact factor: 3.685

7.  Semantic dementia combined with motor neuron disease.

Authors:  Sook Hui Kim; Sang Won Seo; Seok Min Go; Mee Kyung Suh; Juhee Chin; Jee Hyang Jeong; Duk L Na
Journal:  J Clin Neurosci       Date:  2009-10-01       Impact factor: 1.961

8.  Continuum of frontal lobe impairment in amyotrophic lateral sclerosis.

Authors:  Jennifer M Murphy; Roland G Henry; Susan Langmore; Joel H Kramer; Bruce L Miller; Catherine Lomen-Hoerth
Journal:  Arch Neurol       Date:  2007-04

9.  A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

Authors:  Alan E Renton; Elisa Majounie; Adrian Waite; Javier Simón-Sánchez; Sara Rollinson; J Raphael Gibbs; Jennifer C Schymick; Hannu Laaksovirta; John C van Swieten; Liisa Myllykangas; Hannu Kalimo; Anders Paetau; Yevgeniya Abramzon; Anne M Remes; Alice Kaganovich; Sonja W Scholz; Jamie Duckworth; Jinhui Ding; Daniel W Harmer; Dena G Hernandez; Janel O Johnson; Kin Mok; Mina Ryten; Danyah Trabzuni; Rita J Guerreiro; Richard W Orrell; James Neal; Alex Murray; Justin Pearson; Iris E Jansen; David Sondervan; Harro Seelaar; Derek Blake; Kate Young; Nicola Halliwell; Janis Bennion Callister; Greg Toulson; Anna Richardson; Alex Gerhard; Julie Snowden; David Mann; David Neary; Michael A Nalls; Terhi Peuralinna; Lilja Jansson; Veli-Matti Isoviita; Anna-Lotta Kaivorinne; Maarit Hölttä-Vuori; Elina Ikonen; Raimo Sulkava; Michael Benatar; Joanne Wuu; Adriano Chiò; Gabriella Restagno; Giuseppe Borghero; Mario Sabatelli; David Heckerman; Ekaterina Rogaeva; Lorne Zinman; Jeffrey D Rothstein; Michael Sendtner; Carsten Drepper; Evan E Eichler; Can Alkan; Ziedulla Abdullaev; Svetlana D Pack; Amalia Dutra; Evgenia Pak; John Hardy; Andrew Singleton; Nigel M Williams; Peter Heutink; Stuart Pickering-Brown; Huw R Morris; Pentti J Tienari; Bryan J Traynor
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

10.  Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study.

Authors:  Aleksey Shatunov; Kin Mok; Stephen Newhouse; Michael E Weale; Bradley Smith; Caroline Vance; Lauren Johnson; Jan H Veldink; Michael A van Es; Leonard H van den Berg; Wim Robberecht; Philip Van Damme; Orla Hardiman; Anne E Farmer; Cathryn M Lewis; Amy W Butler; Olubunmi Abel; Peter M Andersen; Isabella Fogh; Vincenzo Silani; Adriano Chiò; Bryan J Traynor; Judith Melki; Vincent Meininger; John E Landers; Peter McGuffin; Jonathan D Glass; Hardev Pall; P Nigel Leigh; John Hardy; Robert H Brown; John F Powell; Richard W Orrell; Karen E Morrison; Pamela J Shaw; Christopher E Shaw; Ammar Al-Chalabi
Journal:  Lancet Neurol       Date:  2010-10       Impact factor: 44.182

View more
  192 in total

Review 1.  Advances in understanding the molecular basis of frontotemporal dementia.

Authors:  Rosa Rademakers; Manuela Neumann; Ian R Mackenzie
Journal:  Nat Rev Neurol       Date:  2012-06-26       Impact factor: 42.937

Review 2.  New approaches to genetic counseling and testing for Alzheimer's disease and frontotemporal degeneration.

Authors:  Jill S Goldman
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

Review 3.  Familial Amyotrophic Lateral Sclerosis.

Authors:  Kevin Boylan
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

4.  Heritability in frontotemporal dementia: more missing pieces?

Authors:  Kieren Po; Felicity V C Leslie; Natalie Gracia; Lauren Bartley; John B J Kwok; Glenda M Halliday; John R Hodges; James R Burrell
Journal:  J Neurol       Date:  2014-08-26       Impact factor: 4.849

Review 5.  Mechanisms of toxicity in C9FTLD/ALS.

Authors:  Tania F Gendron; Veronique V Belzil; Yong-Jie Zhang; Leonard Petrucelli
Journal:  Acta Neuropathol       Date:  2014-01-07       Impact factor: 17.088

6.  Frontotemporal dementia with a C9ORF72 expansion in a Swedish family: clinical and neuropathological characteristics.

Authors:  Maria Landqvist Waldö; Lars Gustafson; Karin Nilsson; Bryan J Traynor; Alan E Renton; Elisabet Englund; Ulla Passant
Journal:  Am J Neurodegener Dis       Date:  2013-11-29

7.  C9ORF72 repeat expansions not detected in a group of patients with schizophrenia.

Authors:  Edward D Huey; Peter L Nagy; Laura Rodriguez-Murillo; Masood Manoochehri; Jill Goldman; Jeffrey Lieberman; Maria Karayiorgou; Richard Mayeux
Journal:  Neurobiol Aging       Date:  2012-10-01       Impact factor: 4.673

Review 8.  Role of the C9ORF72 Gene in the Pathogenesis of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.

Authors:  Zongbing Hao; Rui Wang; Haigang Ren; Guanghui Wang
Journal:  Neurosci Bull       Date:  2020-08-29       Impact factor: 5.203

9.  C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD.

Authors:  Elaine Y Liu; Jenny Russ; Kathryn Wu; Donald Neal; Eunran Suh; Anna G McNally; David J Irwin; Vivianna M Van Deerlin; Edward B Lee
Journal:  Acta Neuropathol       Date:  2014-05-08       Impact factor: 17.088

Review 10.  Diagnosis and management of behavioral issues in frontotemporal dementia.

Authors:  Masood Manoochehri; Edward D Huey
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.